NEWS HIGHLIGHTSMedia Articles Related to Ovide (Malathion Topical)
Bill Seeks to Provide Acupuncture to U.S. Veterans
Source: MedicineNet Acupuncture Specialty [2017.06.16]
Title: Bill Seeks to Provide Acupuncture to U.S. Veterans
Category: Health News
Created: 6/15/2017 12:00:00 AM
Last Editorial Review: 6/16/2017 12:00:00 AM
Epigenetic Enzyme Inhibitors Are Broad-Spectrum Antivirals
Source: Medscape Allergy & Clinical Immunology Headlines [2017.09.26]
Epigenetic activation of innate immunity provided a novel broad-spectrum antiviral effect.
Medscape Medical News
Narrow Networks Get Tighter for Mental Health Specialists
Source: Medscape Business of Medicine Headlines [2017.09.26]
If you've got a plan offered on the federal health insurance marketplace and you're looking for a therapist, you may have to look hard: The average provider network includes only 11% of all the mental health care providers in a given market, according to a recent study.
Kaiser Health News
Predictors for and Coverage of Flu Vaccine in HIV Patients
Source: Medscape Allergy & Clinical Immunology Headlines [2017.09.25]
How likely are HIV-infected individuals to be vaccinated against influenza, and what are the reasons for not doing so? A survey of HIV-positive patients provides insight.
HIV Medicine
Published Studies Related to Ovide (Malathion Topical)
Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. [2010.12]
BACKGROUND: Reports of treatment failure of head lice have become increasingly common. Oral ivermectin has been proposed as a potential alternative for the treatment of head lice infestation. The aim of this study was to compare the efficacy of oral ivermectin with topical malathion lotion in the treatment of head lice... CONCLUSIONS: Oral ivermectin is a promising effective approach for the treatment of head lice and could be an ideal substitute for conventional pediculicides. (c) The Author * Journal compilation (c) Blackwell Verlag GmbH, Berlin.
Oral ivermectin versus malathion lotion for difficult-to-treat head lice. [2010.03.11]
BACKGROUND: Head-lice infestation is prevalent worldwide, especially in children 3 to 11 years old. Topical insecticides (i.e., pyrethroids and malathion) used as a lotion, applied twice at an interval of 7 to 11 days, are typically used for treatment. Resistance of lice to insecticides, particularly pyrethroids, results in treatment failure. The efficacy of alternative agents is controversial... CONCLUSIONS: For difficult-to-treat head-lice infestation, oral ivermectin, given twice at a 7-day interval, had superior efficacy as compared with topical 0.5% malathion lotion, a finding that suggests that it could be an alternative treatment. (ClinicalTrials.gov number, NCT00819520.) 2010 Massachusetts Medical Society
Randomised, controlled, assessor blind trial comparing 4% dimeticone lotion with 0.5% malathion liquid for head louse infestation. [2007.11.07]
BACKGROUND: Malathion 0.5% has been the most prescribed pediculicide in the United Kingdom for around 10 years, and is widely used in Europe and North America...
Efficacy of a reduced application time of Ovide lotion (0.5% malathion) compared to Nix creme rinse (1% permethrin) for the treatment of head lice. [2004.11]
Our objective was to conduct a randomized, investigator-blinded evaluation of the pediculicidal and ovicidal activity of a reduced application time (20 minutes) of Ovide (0.5% malathion) compared to Nix (1% permethrin) in a south Florida population infested with Pediculus humanus capitis...
Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. [2010.08.13]
Summary Background: Reports of treatment failure of head lice have become increasingly common...
Clinical Trials Related to Ovide (Malathion Topical)
Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice [Completed]
In this study, 24 adult patients with head lice will be treated with a topical malathion
head lice treatment; 12 patients will be treated with a novel product, Malathion Gel, 0. 5%,
and other 12 patients will be treated with Ovide Lotion 0. 5% marketed by Taro
Pharmaceuticals USA, Inc. The primary objective of this study is to compare the blood level
exposure of Malathion 0. 5% Gel to that of the OVIDE Lotion 0. 5%.
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Completed]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for
head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of
an established head lice treatment. The new formulation has been evaluated in 2 previous
studies of patients 2 years of age and older.
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice [Completed]
Current treatments for head lice include over-the-counter products such as permethrin and
prescription products such as OVIDE (malathion 0. 5%) lotion. In a previous phase II study,
a novel, easy-to-use malathion 0. 5% formulation was found to be a safe treatment for head
lice. The current study will compare the efficacy and safety of this novel formulation of
malathion with OVIDE and with an over-the-counter permethrin product.
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Completed]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for
head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of
an established head lice treatment. The new formulation has been evaluated in 2 previous
studies of patients 2 years of age and older.
Ivermectin in the Treatment of Head Lice [Completed]
The purpose of this study is to compare 2 single doses of ivermectin as tablets with 2
single applications of malathion 0. 5% lotion (Days 1 and 8) in clearing head lice, in
patients who have recently used standard head lice treatments without success.
Reports of Suspected Ovide (Malathion Topical) Side Effects
Application Site Burn (3),
Burns Second Degree (3),
Fall (2),
Loss of Consciousness (2),
Skin Infection (2),
Accidental Exposure (2),
Chemical Injury (2),
Muscle Atrophy (1),
Peroneal Nerve Palsy (1),
Oedema Peripheral (1), more >>
|
